AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04019639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: application of CG Paste+EasyFoam
Description: Prior to application of CG paste, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. After this, hemostasis is performed by an electrocoagulator and the medical device is applied to the affected area. During the procedure, remove the packaging material and remove the syringe to remove the protective cap in front of the syringe. Slowly push the syringe plunger and apply the contents to the area where you want to use. Depending on the location and size of the wound area, an injection cap can be used. Apply CG paste and apply Easyfoam to finish the dressing.
Study NCT04019639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: application of EasyFoam
Description: Prior to applying EasyFoam, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. Marginal resection is performed until the necrotic tissue is removed sufficiently and pin point bleeding is seen on the wound. After that, hemostasis is done with an electrocoagulator and EasyFoam is applied to the affected area.
Study NCT01044524 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SLV 334
Description: 2000 mg via i.v. solution
Study NCT04262219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iShare
Description: The iShare intervention consists of a two-episode educational podcast series containing information about breast cancer patients' sexual problems, approaches for addressing sexual concerns, and information about discussing sexual concerns with patients, such as initiating a conversation about sexual health and asking questions to assess sexual concern. Both episodes feature expert guests and relevant discussions or case studies.
Study NCT00945737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein; 25 grams/day
Description: Soy protein
Study NCT00945737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control protein
Description: Milk protein
Study NCT04021433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Repeated doses of IM/SC ketamine up to 3 times a week
Study NCT02582489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate
Description: Subjects undergoing autologous bone marrow aspirate concentrate will receive an intra-articular injection into the affected knee.
Study NCT02582489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Meniscectomy
Description: All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.
Study NCT02582489 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Meniscectomy
Description: All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.
Study NCT01341704 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP3-LSP/AlOH
Description: 30 µg of test vaccine MSP3-LSP/AlOH, administered by subcutaneous route according to the following schedule:- Primary administration: Three doses administered at 4 weeks interval: D0, D28 (± 2 days), D56 (± 4 days)~Secondary administration (Boost):~Year 1: One dose 3 months after the third dose Year 2: Two doses, given exactly one year after the date corresponding to the third dose and the first boost given during Year 1
Study NCT01341704 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Verorab Vaccine
Description: The Verorab rabies vaccine will be given as control for the primary series of the experimental vaccine. It consists of inactivated rabies virus produced in vero cells (Wistar Rabies PM/W138 1503-3M (inactivated). Manufacturer SANOFI PASTEUR SA. Presentation is 0.5 ml per dose in a pre-filled syringe.
Study NCT01341704 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl/Normal Saline
Description: 0.5 ml per dose; to be given as control for the secondary/booster doses of experimental vaccine
Study NCT00976365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: THL-P
Description: 20ml/bottle, TID, 24weeks
Study NCT00976365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: THL-P
Description: 20ml/bottle, TID, 24weeks
Study NCT00352118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: subcutaneously on Days 5-14, repeating every 3 weeks for 2 courses.
Study NCT00352118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: If applicable on day 5, repeating every 3 weeks for 2 courses.
Study NCT00352118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.
Study NCT00352118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Intravenous over 1 hour on day 1.
Study NCT00352118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Intravenous continuously on days 1-4.
Study NCT00352118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: As appropriate, neck dissection.
Study NCT00352118 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 60 Gy 5 days/week x 6 weeks with cisplatin
Study NCT00729742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: erlotinib + dalotuzumab
Description: Part II: All patients will receive 1 week of erlotinib 150 mg tablets per day.~Arm 1: Patients who experience a PET response will continue on erlotinib monotherapy until disease progression.~Arm 2: Patients who fail to receive a PET response will continue to take erlotinib in combination with dalotuzumab 10 mg/kg IV infusion once weekly. At the time of disease progression, patients on erlotinib monotherapy will be offered to crossover to dalotuzumab 10 mg/kg IV infusion once weekly in combination with erlotinib.
Study NCT00729742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: erlotinib monotherapy
Description: Part I: All patients will receive erlotinib 150 mg tablets per day until disease progression.
Study NCT02349412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early palliative care
Study NCT03427892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders.
Study NCT01029756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Laryngoscope
Description: Device used to gain a direct view of the vocal cords, to enable an endotracheal tube to be passed into the trachea at induction of anaesthesia.
Study NCT01029756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pentax AWS Videolaryngoscope
Description: Self-contained video laryngoscope with an integral colour-viewing screen mounted on the handle. A camera at the tip transmits an indirect image, which obviates the need to obtain a direct view of the vocal cords, when passing an endotracheal tube on induction of anaesthesia.
Study NCT00737178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CuT380A
Description: Comparison of different timing of IUD insertion
Study NCT00587067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOXURIDINE
Description: \[0.16\* mg/kg/day X 30 ml\] / pump flow rate~\* If the patient is >25% above ideal body weight, the dose of FUDR will be calculated from an average of the patients actual and ideal body weights. For example, for a patient who is 5ft. 10 inches and weighs 100kg: Ideal Body Weight (kg) = 50 + (2.3 X height in inches over 5 feet) = 50 + (2.3 X 10) = 73 Weight Used for dose calculation = (100 + 73)/2 = 86.5 Therefore, FUDR Dose will be = (0.16 X 86.5 X 30)/Flow Rate If no dose modification due to toxicity is required, the dosages given above (adjusted for changes in weight and pump flow rate) will be repeated on Day 1 of Week 1 of Cycle 2 and all subsequent cycles.
Study NCT04269616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order of pictographs provided to participants
Description: The pictographs presented to participants about survival and disability were varied in the order in which they were presented (i.e. survival or disability information first).
Study NCT04269616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level of description in survival pictograph
Description: The pictographs presented to participants about survival and disability were varied in the level of description provided in the survival pictograph (i.e. only numerical data, or also a description of course of NICU stay).
Study NCT01799889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib MM
Description: Entospletinib MM tablet administered orally
Study NCT01799889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib SDD
Description: Entospletinib SDD tablet administered orally
Study NCT02593500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonida Pulmictan® 200 µg
Study NCT02593500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 200 µg
Study NCT04415801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Repeated removal and re-placement of healing and prosthetic abutments
Description: Repeated removal and re-placement of healing and prosthetic abutments
Study NCT01147822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg administered once daily orally continuous dosing
Study NCT01147822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
Study NCT03928366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: sedation
Study NCT03928366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: remifentanil
Study NCT02598453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months
Study NCT00547144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenoulsy once a week according to protocol schedule
Study NCT00547144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Immunotherapy
Description: The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)
Study NCT03938571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal Switch
Study NCT03938571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal Switch
Study NCT01042795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg daily X 16 weeks
Study NCT01586195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib 960 mg BID
Study NCT00320047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Participants will take baclofen 3 times a day, before meals, for 10 weeks. Baclofen dosages will be low to begin, followed by a gradual increase over a 2-week period. Upon reaching the maximum tolerated dose of baclofen, participants will continue at this dosage level until Week 11, at which time the dose will be gradually decreased. If any serious side effects occur, baclofen dosage will be decreased to the previous tolerated dosage level.
Study NCT00296244 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Steroids
Description: Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.
Study NCT00296244 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Basiliximab
Description: Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.
Study NCT00296244 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.
Study NCT00296244 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enteric-coated Mycophenolic acid (EC-MPA)
Description: This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
Study NCT03356717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention with observer tool
Description: To assess if the use of an observer tool by observers during high fidelity simulation improves learning outcomes
Study NCT03356717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: without observer tool
Study NCT02420639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.
Description: Use of the Esophageal Cooling Device for control of patient temperature.
Study NCT02899520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference method
Description: Electrostimulation associated to perineal training
Study NCT02899520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CMP ® method
Description: Method based on Knowledge and Control of Perineum
Study NCT01077557 — intervention group
Intervention type: OTHER
Intervention: No Antiretroviral (ARV) Drug Exposure
Description: No pharmacy dispensing of an ARV drug
Study NCT01077557 — intervention group
Intervention type: DRUG
Intervention: Any Antiretroviral (ARV) Drug Exposure
Description: Pharmacy dispensing claim for any ARV drug
Study NCT02957201 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples at baseline and 3 timepoints for EPC analysis
Study NCT01781897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)
Study NCT01781897 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)
Study NCT01781897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mosapride
Description: Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
Study NCT01781897 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: mosapride
Description: Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
Study NCT01182025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western therapy
Description: Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;
Study NCT01182025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiyanping Injection
Description: Dosage for child medication:~5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor.
Study NCT01182025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiyanping Injection with western medicine
Description: 1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Symptomatic treatment using the same treatment methods in Xiyanpin injection group.
Study NCT01803438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoballoon ablation system
Study NCT01803438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic Drugs
Description: AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
Study NCT01294423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose
Study NCT01294423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose
Study NCT01294423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for Dapagliflozin 5mg/10mg oral dose
Study NCT04933318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneus electrical nerve stimulation (TENS)- analgesic current therapy
Study NCT04933318 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: shamTENS
Description: shamTranscutaneus electrical nerve stimulation (shamTENS)- analgesic current therapy
Study NCT04933318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IFC
Description: Interferential current therapy (IFC)- analgesic current therapy
Study NCT04933318 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: shamIFC
Description: shamInterferential current therapy (shamIFC)- analgesic current therapy
Study NCT00641056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Once Weekly
Description: subcutaneous injection, 2.0mcg, once weekly
Study NCT00641056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: subcutaneous injection, variable dose, QD
Study NCT00301834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Study NCT01238900 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Description: Endoscopic Retrograde Cholangiopancreatography (ERCP) with placement of metal stent in the bile duct
Study NCT01034176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: 500 mg tablet, daily, 30 days
Study NCT01034176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no dose, tablet, daily, 30 days
Study NCT01451892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance Therapy
Description: overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
Study NCT01451892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient education
Description: overweight individuals participating in a patient education program
Study NCT03559231 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dFTRD
Description: Duodenal Full-Thickness Resection
Study NCT03559231 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMR
Description: Endoscopic Mucosal Resection
Study NCT00301834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study NCT00301834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00301834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00301834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00301834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study NCT00301834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Study NCT00301834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT00301834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00301834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Study NCT03884010 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Cross-sectional
Study NCT02517749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chest Drain Insertion and Talc Pleurodesis
Study NCT02517749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling Pleural Catheter Insertion and Talc Pleurodesis
Study NCT04887363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core exercise
Description: Participants will receive12-week, 60 minutes, 36-session exercise-based core stability training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.